Identification of novel bacterial DNA gyrase inhibitors: An in silico study. 2016

Hamzeh Rahimi, and Ali Najafi, and Habib Eslami, and Babak Negahdari, and Mehrdad Moosazadeh Moghaddam
Molecular Medicine Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.

Owing to essential role in bacterial survival, DNA gyrase has been exploited as a validated drug target. However, rapidly emerging resistance to gyrase-targeted drugs such as widely utilized fluoroquinolones reveals the necessity to develop novel compounds with new mechanism of actions against this enzyme. Here, an attempt has been made to identify new drug-like molecules for Shigella flexneri DNA gyrase inhibition through in silico approaches. The structural similarity search was carried out using the natural product simocyclinone D8, a unique gyrase inhibitor, to virtually screen ZINC database. A total of 11830 retrieved hits were further screened for selection of high-affinity compounds by implementing molecular docking followed by investigation of druggability according to Lipinski's rule, biological activity and physiochemical properties. Among the hits initially identified, three molecules were then confirmed to have reasonable gyrase-binding affinity and to follow Lipinski's rule. Based on these in silico findings, three compounds with different chemical structures from previously identified gyrase inhibitors were proposed as potential candidates for the treatment of fluoroquinolone-resistant strains and deserve further investigations.

UI MeSH Term Description Entries

Related Publications

Hamzeh Rahimi, and Ali Najafi, and Habib Eslami, and Babak Negahdari, and Mehrdad Moosazadeh Moghaddam
March 1988, The Journal of antibiotics,
Hamzeh Rahimi, and Ali Najafi, and Habib Eslami, and Babak Negahdari, and Mehrdad Moosazadeh Moghaddam
November 1993, The Journal of antibiotics,
Hamzeh Rahimi, and Ali Najafi, and Habib Eslami, and Babak Negahdari, and Mehrdad Moosazadeh Moghaddam
May 2013, Bioorganic & medicinal chemistry letters,
Hamzeh Rahimi, and Ali Najafi, and Habib Eslami, and Babak Negahdari, and Mehrdad Moosazadeh Moghaddam
September 2014, Molecular informatics,
Hamzeh Rahimi, and Ali Najafi, and Habib Eslami, and Babak Negahdari, and Mehrdad Moosazadeh Moghaddam
May 1997, The Journal of antibiotics,
Hamzeh Rahimi, and Ali Najafi, and Habib Eslami, and Babak Negahdari, and Mehrdad Moosazadeh Moghaddam
October 2014, Current opinion in pharmacology,
Hamzeh Rahimi, and Ali Najafi, and Habib Eslami, and Babak Negahdari, and Mehrdad Moosazadeh Moghaddam
September 2022, ACS omega,
Hamzeh Rahimi, and Ali Najafi, and Habib Eslami, and Babak Negahdari, and Mehrdad Moosazadeh Moghaddam
July 2016, The Journal of antimicrobial chemotherapy,
Hamzeh Rahimi, and Ali Najafi, and Habib Eslami, and Babak Negahdari, and Mehrdad Moosazadeh Moghaddam
March 2013, Journal of biomolecular screening,
Hamzeh Rahimi, and Ali Najafi, and Habib Eslami, and Babak Negahdari, and Mehrdad Moosazadeh Moghaddam
January 2013, International journal of antimicrobial agents,
Copied contents to your clipboard!